Nuevolution is determined to develop a number of attractive programs up to a clinical Candidate or to an early clinical stage. We embrace partnerships to advance novel promising programmes rapidly through clinical development to commercialization and benefit for the patients.
Nuevolution has successfully applied its drug discovery platform to establish a portfolio of internal pipeline programmes within oncology, immuno-oncology and inflammatory (autoimmune) diseases – small molecule programmes that have the potential of providing significant improved therapies for patients.
Our current programs available for licensing are:
• RORγt – Orally available RORγt inverse agonists for inflammatory indications
• BET-BRD – First-in-class BET domain selective bromodomain 1 inhibitors
Further information on our pipeline projects is available in the pipeline section.
The Almirall and Nuevolution partnership is a global strategic collaboration focusing on the development and commercialization of Nuevolution’s novel RORgt inverse agonist (inhibitor) program for treatment of inflammatory skin diseases and disorders as well as for treatment of psoriatic arthritis. Both parties will work in this research collaboration towards to successful identification of additional RORgt inhibitors, where Almirall has an exclusive option for use within dermatology and where Nuevolution has optional use in areas outside the field of collaboration.